JP2018519818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519818A5 JP2018519818A5 JP2017566354A JP2017566354A JP2018519818A5 JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5 JP 2017566354 A JP2017566354 A JP 2017566354A JP 2017566354 A JP2017566354 A JP 2017566354A JP 2018519818 A5 JP2018519818 A5 JP 2018519818A5
- Authority
- JP
- Japan
- Prior art keywords
- mol
- composition
- lipid
- mixture
- dodap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 150000002632 lipids Chemical class 0.000 claims 16
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 7
- 230000009368 gene silencing by RNA Effects 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- -1 nucleic acid compound Chemical class 0.000 claims 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 5
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims 5
- 102000000412 Annexin Human genes 0.000 claims 4
- 108050008874 Annexin Proteins 0.000 claims 4
- 108050005845 Annexin A11 Proteins 0.000 claims 4
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 4
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical group C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 4
- 230000007935 neutral effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 101000614345 Homo sapiens Prolyl 4-hydroxylase subunit alpha-1 Proteins 0.000 claims 2
- 102100040477 Prolyl 4-hydroxylase subunit alpha-1 Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229960001295 tocopherol Drugs 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000010384 tocopherol Nutrition 0.000 claims 2
- 239000011732 tocopherol Substances 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000003611 tocopherol derivatives Chemical class 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190583P | 2015-07-09 | 2015-07-09 | |
| US62/190,583 | 2015-07-09 | ||
| PCT/US2016/041776 WO2017008076A1 (en) | 2015-07-09 | 2016-07-11 | Compositions and methods for treating lung diseases and lung injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519818A JP2018519818A (ja) | 2018-07-26 |
| JP2018519818A5 true JP2018519818A5 (enExample) | 2019-09-12 |
| JP6884714B2 JP6884714B2 (ja) | 2021-06-09 |
Family
ID=57686097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566354A Active JP6884714B2 (ja) | 2015-07-09 | 2016-07-11 | 肺疾患及び肺損傷を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180200186A1 (enExample) |
| EP (1) | EP3319976B1 (enExample) |
| JP (1) | JP6884714B2 (enExample) |
| AU (2) | AU2016291228B2 (enExample) |
| CA (1) | CA2989884A1 (enExample) |
| ES (1) | ES2898340T3 (enExample) |
| WO (1) | WO2017008076A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3718532A1 (en) | 2005-12-08 | 2020-10-07 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| US20170049739A1 (en) | 2013-10-25 | 2017-02-23 | Insmed Incorporated | Prostacyclin compounds, compositions and methods of use thereof |
| PL3466432T3 (pl) | 2014-05-15 | 2021-02-08 | Insmed Incorporated | Sposoby leczenia zakażeń płuc niegruźliczymi mykobakteriami |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| CN112955134A (zh) | 2018-07-19 | 2021-06-11 | 英倍尔药业股份有限公司 | 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送 |
| CA3111484A1 (en) * | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| EA202190688A1 (ru) | 2018-10-09 | 2021-06-07 | Дзе Юниверсити Оф Бритиш Коламбиа | Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы |
| CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
| MX2021013329A (es) | 2019-04-29 | 2022-03-17 | Insmed Inc | Composiciones de polvo seco de los profarmacos de treprostinil y métodos de uso de las mismas. |
| CA3164248A1 (en) * | 2019-12-05 | 2021-06-10 | Board Of Regents, The University Of Texas System | Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis |
| MX2022012683A (es) | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
| KR20230038217A (ko) * | 2020-07-10 | 2023-03-17 | 제네반트 사이언시즈 게엠베하 | 폐에 치료제를 전달하기 위한 지질 나노입자 |
| EP4213882A4 (en) | 2020-09-15 | 2025-02-26 | Verve Therapeutics, Inc. | LIPID FORMULATIONS FOR GENE EDITING |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| KR20240005692A (ko) | 2021-03-22 | 2024-01-12 | 리코드 테라퓨틱스, 인크. | 세포로의 표적화 전달을 위한 조성물 및 방법 |
| CN113058042B (zh) * | 2021-04-01 | 2023-06-30 | 易慧生物技术(上海)有限公司 | 一种可鼻喷的稳定递载rna分子的脂质纳米颗粒制备方法 |
| CN115245559A (zh) * | 2021-04-25 | 2022-10-28 | 上海萨美细胞技术有限公司 | 一种用于治疗肺损伤的药物 |
| CN117881789A (zh) * | 2021-06-09 | 2024-04-12 | 瑞科德治疗公司 | 多核苷酸组合物、相关制剂、及其使用方法 |
| WO2023019192A1 (en) * | 2021-08-11 | 2023-02-16 | Board Of Regents, The University Of Texas System | Dry liposome formulations and related methods thereof |
| PL438742A1 (pl) * | 2021-08-14 | 2023-02-20 | Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością | Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną |
| EP4226949A1 (en) * | 2022-02-14 | 2023-08-16 | Pantherna Therapeutics GmbH | Preparation for use in a method for the treatment and/or prevention of a disease |
| WO2024242216A1 (ko) * | 2023-05-23 | 2024-11-28 | 주식회사 케이더블유바이오 | 대식세포 표적화 리포좀 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721612A (en) * | 1984-04-12 | 1988-01-26 | The Liposome Company, Inc. | Steroidal liposomes |
| US4861580A (en) * | 1985-10-15 | 1989-08-29 | The Liposome Company, Inc. | Composition using salt form of organic acid derivative of alpha-tocopheral |
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2004267317A1 (en) * | 2003-08-20 | 2005-03-03 | Eisai R&D Management Co., Ltd. | Method of detecting effect of controlling synoviolin activity |
| WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| CA2740000C (en) * | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2011108955A1 (en) * | 2010-03-03 | 2011-09-09 | Universidade De Coimbra | Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s) |
| EP3456827A3 (en) * | 2010-06-02 | 2019-05-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2014052634A1 (en) * | 2012-09-27 | 2014-04-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
-
2016
- 2016-07-11 ES ES16822088T patent/ES2898340T3/es active Active
- 2016-07-11 JP JP2017566354A patent/JP6884714B2/ja active Active
- 2016-07-11 EP EP16822088.7A patent/EP3319976B1/en active Active
- 2016-07-11 CA CA2989884A patent/CA2989884A1/en not_active Abandoned
- 2016-07-11 WO PCT/US2016/041776 patent/WO2017008076A1/en not_active Ceased
- 2016-07-11 AU AU2016291228A patent/AU2016291228B2/en active Active
- 2016-07-11 US US15/742,812 patent/US20180200186A1/en not_active Abandoned
-
2020
- 2020-05-22 AU AU2020203367A patent/AU2020203367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519818A5 (enExample) | ||
| Pramanik et al. | Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases | |
| Hernandez et al. | Liposome based drug delivery as a potential treatment option for Alzheimer's disease | |
| Mehta et al. | Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future | |
| Jain et al. | Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer | |
| Chan et al. | Advances in device and formulation technologies for pulmonary drug delivery | |
| JP2007508353A5 (enExample) | ||
| JP2018528184A5 (enExample) | ||
| JP2018516545A5 (enExample) | ||
| JP2015523355A5 (enExample) | ||
| JP2015515992A5 (enExample) | ||
| Jessamine et al. | The application of nanoparticles as advanced drug delivery systems in Attenuating COPD | |
| Lu et al. | Environment‐responsive Lipid/siRNA nanoparticles for cancer therapy | |
| JP2014077003A5 (enExample) | ||
| Ashique et al. | Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC) | |
| JP2010508365A5 (enExample) | ||
| Homayoonfal et al. | Application of nanoparticles for efficient delivery of quercetin in cancer cells | |
| Yong et al. | Natural products-based inhaled formulations for treating pulmonary diseases | |
| Mao et al. | Theranostic lipid nanoparticles for renal cell carcinoma | |
| Shanmugam et al. | Aerosol delivery of paclitaxel-containing self-assembled nanocochleates for treating pulmonary metastasis: An approach supporting pulmonary mechanics | |
| Sadhu et al. | In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine | |
| Jani et al. | Focused insights into liposomal nanotherapeutics for antimicrobial treatment | |
| Xie et al. | A new core–shell-type nanoparticle loaded with paclitaxel/norcantharidin and modified with APRPG enhances anti-tumor effects in hepatocellular carcinoma | |
| Ji et al. | Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a “nanoguard” for synergistic treatment of synucleinopathies | |
| Liu et al. | Ginger-derived exosome-like nanoparticles: a representative of plant-based natural nanostructured drug delivery system |